BDX (Becton, Dickinson And Company) — AI Stock Analysis & Recommendation

Research of September 24, 2026 · Healthcare / Surgical & Medical Instruments & Apparatus

TradeFlare's AI research teams rate BDX a HOLD. The latest price is $195.16.

The research plan

• Entry: $179.23
• Time horizon: days

The current market regime and stock-specific factors do not support a BUY recommendation at this time.

Why

The current market regime and stock-specific factors do not support a BUY recommendation at this time. Catalysts to watch: Continued operational advancements by BDX; Positive developments in addressing legal and regulatory challenges; Favorable shifts in analyst sentiment. Key risks: Ongoing product liability lawsuits (Bard PowerPort); Continued regulatory and legal scrutiny (Alaris Infusion Pump); Potential for further financial strain due to liquidity concerns.

What could push BDX higher

• Continued operational advancements by BDX.
• Positive developments in addressing legal and regulatory challenges.
• Favorable shifts in analyst sentiment.

Key risks for BDX

• Ongoing product liability lawsuits (Bard PowerPort).
• Continued regulatory and legal scrutiny (Alaris Infusion Pump).
• Potential for further financial strain due to liquidity concerns.

What each AI research team found

Fundamental team: Neutral · valuation: fair

BDX presents a mixed fundamental picture with a strong competitive position and robust free cash flow, but faces headwinds from negative earnings growth and tight liquidity. The fair valuation, supported by analyst consensus and a reasonable forward P/E, suggests a neutral stance, awaiting clearer signs of earnings recovery to justify a bullish outlook.

• BDX exhibits a strong gross margin (46.94%) and positive revenue growth (5.4% YoY), but has experienced a significant earnings decline (-31.4% YoY).
• Valuation appears fair, with an elevated trailing P/E (30.96x) offset by a more reasonable forward P/E (13.48x) and a PEG ratio of 1.11, supported by strong free cash flow generation ($2.534 billion TTM).
• Liquidity ratios (current ratio 0.865, quick ratio 0.327) are concerning, indicating potential short-term financial strain.

Technical team: Neutral

The technical analysis indicates a neutral stance for BDX as the price consolidates near a key resistance level. With below-average volume and neutral to slightly bearish momentum, a short-term pullback is more likely than a breakout. The current price is considered an unfavorable entry point given the proximity to resistance.

• Price is consolidating near resistance R1 ($179.45) with mixed signals from moving averages, suggesting a neutral outlook with potential for a short-term upward move if resistance is broken.
• The stock is consolidating near resistance with below-average volume, suggesting a neutral stance with potential for a short-term pullback to support.
• Momentum indicators are neutral to slightly bearish, with the price approaching resistance, suggesting a potential short-term pullback.

Sentiment team: Neutral

Becton, Dickinson and Company (BDX) sentiment is currently neutral across news, social media, and analyst views. While operational advancements and dividend payments offer some positive drivers, significant legal and regulatory concerns, including SEC settlements and ongoing litigation, weigh heavily on the stock. The stock's underperformance and recent negative reactions to leadership changes contribute to a...

• BDX news coverage is neutral, highlighting operational advancements and significant legal/regulatory challenges, alongside mixed stock performance. (Score: 0.042)
• BDX exhibits neutral sentiment from operational advancements and positive analyst outlook, countered by regulatory scrutiny and past litigation. (Score: 0.04)
• BDX exhibits neutral sentiment driven by mixed news, including litigation and regulatory pressures, offset by a stable dividend and automation deployments, with analysts maintaining a 'Hold' consensus. (Consensus: Hold)

Risk team: High

BDX presents a HIGH overall risk due to significant company-specific legal and regulatory challenges, compounded by a history of deep drawdowns and potential liquidity concerns. The substantial product liability and ongoing regulatory scrutiny create a high degree of uncertainty, warranting a SMALL position size and aggressive risk management.

• Product Liability (Bard PowerPort): Thousands of pending lawsuits and a recent large verdict against C.R. Bard for alleged defects in Bard PowerPort devices pose a significant legal and financial risk.
• Regulatory and Legal Scrutiny (Alaris Infusion Pump): An SEC order and a substantial civil penalty for misstatements related to the Alaris infusion pump indicate ongoing regulatory oversight and potential for future issues.
• Deep Drawdown (1Y): The stock has experienced a significant drawdown of over 41% in the past year, indicating substantial price volatility and potential for sharp declines.

BDX at a glance

Market value	$53.5B
Price / earnings	59.2
Revenue growth (year over year)	17.4%
Profit margin	4.0%
Debt / equity	0.55

Every AI call on BDX since September 9, 2026, and what happened next (5 calls) →

Research of September 24, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.